CORRECTION article

Front. Pharmacol., 06 September 2022

Sec. Drugs Outcomes Research and Policies

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.999301

Corrigendum: Impact of the COVID-19 pandemic on the diagnosis of tuberculosis in Brazil: Is the WHO end TB strategy at risk?

  • 1. Health Science Graduate Program, Universidade Federal de Sergipe, São Cristóvão, Brazil

  • 2. Parasitic Biology Graduate Program, Universidade Federal de Sergipe, São Cristóvão, Brazil

  • 3. Tropical Medicine Graduate Program, Universidade Federal de Pernambuco, Recife, Brazil

  • 4. Department of Medicine, Universidade Federal de Sergipe, Aracaju, Brazil

  • 5. Department of Health Education, Universidade Federal de Sergipe, Lagarto, Brasil

  • 6. Department of Nursing, Universidade Federal de Sergipe, Lagarto, Brasil

  • 7. Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal

  • 8. College of Pharmaceutical Sciences, Federal University of Vale do São Francisco (UNIVASF), Petrolina, Brazil

  • 9. Department of Medicine, Universidade Federal de Alagoas, Arapiraca, Brazil

  • 10. Department of Morphology, Universidade Federal de Sergipe, São Cristóvão, Brazil

  • 11. Laboratory of Immunology and Molecular Biology, University Hospital, Universidade Federal de Sergipe, Aracaju, Brazil

In the published article, there was an error in the Funding statement. The manuscript was published without due mention of the funding agency. The correct Funding statement appears below.

“Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Portugal, ref. UID/04413/2020.”

In addition, the article was published without including the acknowledgments. The correct Acknowledgments statement appears below.

“Foundation for Science and Technology (Fundação para a Ciência e tecnologia) for funds to GHTM – UID/04413/2020”

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

tuberculosis, COVID-19, COVID-19 pandemic, end TB strategy, global health

Citation

Rosário Souza M, Silva da Paz W, dos Santos Sales VB, Hilario de Jesus GF, dos Santos Tavares D, Almeida Lima SVM, Lopes Sousa ÁF, Vieira de Melo E, Feliciano do Carmo R, Freire de Souza CD and Bezerra-Santos M (2022) Corrigendum: Impact of the COVID-19 pandemic on the diagnosis of tuberculosis in Brazil: Is the WHO end TB strategy at risk?. Front. Pharmacol. 13:999301. doi: 10.3389/fphar.2022.999301

Received

20 July 2022

Accepted

25 July 2022

Published

06 September 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Álvaro Francisco Lopes Sousa,

This article was submitted to Drugs Outcomes Research and Policies, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics